Dr. Michael Solomon has served on Protara’s board of directors since May 2018. He currently serves as Chief Executive Officer and on the board of directors of Ribometrix, Inc., a company focused on targeting RNA with small molecules, and has over 20 years of experience in the biotech industry, with the last 14 years focused on creating and operating early-stage companies. Most recently, Dr. Solomon served as a Venture Partner at SV Health Investors from December 2016 until December 2018 and as Chief Operating Officer at Decibel Therapeutics, Inc., a biotech company focused on hearing disorders, from 2015 until 2016, where he led the creation of Decibel’s business plan and its capital raise of $52 million.